Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Anti-IL-4 receptor alpha monoclonal antibodies

12 evidence topics · 8 sources

CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label
Week 24 outcomeStudy A dupilumab (N=68)Study A placebo (N=68)Study A difference or odds ratio (95% CI)Study C dupilumab (N=73)Study C placebo (N=75)Study C difference or odds ratio (95% CI)
ISS7, LS mean change (SE)“-10.44 (0.92)”“-6.02 (0.94)”“-4.42 (-6.84, -2.01)”“-8.50 (1.39)”“-6.13 (1.38)”“-2.37 (-4.48, -0.27)”
UAS7, LS mean change (SE)“-20.99 (1.77)”“-11.95 (1.81)”“-9.04 (-13.68, -4.40)”“-15.61 (2.62)”“-11.27 (2.61)”“-4.34 (-8.31, -0.36)”
UAS7 ≤6, n (%)“32 (47.1)”“16 (23.5)”“3.23 (1.43, 7.27)”“29 (39.7)”“17 (22.7)”“3.05 (1.32, 7.02)”
UAS7 = 0, n (%)“22 (32.4)”“9 (13.2)”“3.09 (1.24, 7.69)”“22 (30.1)”“13 (17.3)”“2.73 (1.15, 6.50)”